Abstract
We report 13 multiple myeloma (MM) or lymphoma patients who were failing PBSC mobilization after disease-specific chemotherapy and granulocyte-CSF (G-CSF), and received plerixafor to successfully collect PBSCs. Patients were considered poor mobilizers when the concentration of PB CD34 cells was always lower than 10 cells/L, during the recovery phase after chemotherapy and/or were predicted to have inadequate PBSC collection to proceed to autologous transplantation. Plerixafor (0.24 mg/kg) was administered subcutaneously for up to three consecutive days, while continuing G-CSF, 10-11 h before the planned leukapheresis. Plerixafor administration was safe and no significant adverse events were recorded. We observed a 4.7 median fold-increase in the number of circulating CD34 cells after plerixafor as compared with baseline CD34 cell concentration (from a median of 6.2 (range 1-12) to 21.5 (range 9-88) cells/L). All patients collected 2 × 10 6 CD34 cells/kg in 1-3 leukaphereses. In all, 5/13 patients have already undergone autograft with plerixafor-mobilized PBSCs, showing a rapid and durable hematological recovery. Our results suggest that the pre-emptive addition of plerixafor to G-CSF after chemotherapy is safe and may allow the rescue of lymphoma and MM patients, who need autologous transplantation but are failing PBSC mobilization.
| Original language | English |
|---|---|
| Pages (from-to) | 356-363 |
| Number of pages | 8 |
| Journal | Bone Marrow Transplantation |
| Volume | 46 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2011 |
Fingerprint
Keywords
- autologous stem cell transplantation
- PBSC mobilization
- plerixafor
- poor mobilizers
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. / D'Addio, A.; Curti, A.; Worel, N.; Douglas, K.; Motta, M. R.; Rizzi, S.; Dan, E.; Taioli, S.; Giudice, V.; Agis, H.; Kopetzky, G.; Soutar, R.; Casadei, B.; Baccarani, M.; Lemoli, R. M.
In: Bone Marrow Transplantation, Vol. 46, No. 3, 03.2011, p. 356-363.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF
AU - D'Addio, A.
AU - Curti, A.
AU - Worel, N.
AU - Douglas, K.
AU - Motta, M. R.
AU - Rizzi, S.
AU - Dan, E.
AU - Taioli, S.
AU - Giudice, V.
AU - Agis, H.
AU - Kopetzky, G.
AU - Soutar, R.
AU - Casadei, B.
AU - Baccarani, M.
AU - Lemoli, R. M.
PY - 2011/3
Y1 - 2011/3
N2 - We report 13 multiple myeloma (MM) or lymphoma patients who were failing PBSC mobilization after disease-specific chemotherapy and granulocyte-CSF (G-CSF), and received plerixafor to successfully collect PBSCs. Patients were considered poor mobilizers when the concentration of PB CD34 cells was always lower than 10 cells/L, during the recovery phase after chemotherapy and/or were predicted to have inadequate PBSC collection to proceed to autologous transplantation. Plerixafor (0.24 mg/kg) was administered subcutaneously for up to three consecutive days, while continuing G-CSF, 10-11 h before the planned leukapheresis. Plerixafor administration was safe and no significant adverse events were recorded. We observed a 4.7 median fold-increase in the number of circulating CD34 cells after plerixafor as compared with baseline CD34 cell concentration (from a median of 6.2 (range 1-12) to 21.5 (range 9-88) cells/L). All patients collected 2 × 10 6 CD34 cells/kg in 1-3 leukaphereses. In all, 5/13 patients have already undergone autograft with plerixafor-mobilized PBSCs, showing a rapid and durable hematological recovery. Our results suggest that the pre-emptive addition of plerixafor to G-CSF after chemotherapy is safe and may allow the rescue of lymphoma and MM patients, who need autologous transplantation but are failing PBSC mobilization.
AB - We report 13 multiple myeloma (MM) or lymphoma patients who were failing PBSC mobilization after disease-specific chemotherapy and granulocyte-CSF (G-CSF), and received plerixafor to successfully collect PBSCs. Patients were considered poor mobilizers when the concentration of PB CD34 cells was always lower than 10 cells/L, during the recovery phase after chemotherapy and/or were predicted to have inadequate PBSC collection to proceed to autologous transplantation. Plerixafor (0.24 mg/kg) was administered subcutaneously for up to three consecutive days, while continuing G-CSF, 10-11 h before the planned leukapheresis. Plerixafor administration was safe and no significant adverse events were recorded. We observed a 4.7 median fold-increase in the number of circulating CD34 cells after plerixafor as compared with baseline CD34 cell concentration (from a median of 6.2 (range 1-12) to 21.5 (range 9-88) cells/L). All patients collected 2 × 10 6 CD34 cells/kg in 1-3 leukaphereses. In all, 5/13 patients have already undergone autograft with plerixafor-mobilized PBSCs, showing a rapid and durable hematological recovery. Our results suggest that the pre-emptive addition of plerixafor to G-CSF after chemotherapy is safe and may allow the rescue of lymphoma and MM patients, who need autologous transplantation but are failing PBSC mobilization.
KW - autologous stem cell transplantation
KW - PBSC mobilization
KW - plerixafor
KW - poor mobilizers
UR - http://www.scopus.com/inward/record.url?scp=79952535006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952535006&partnerID=8YFLogxK
U2 - 10.1038/bmt.2010.128
DO - 10.1038/bmt.2010.128
M3 - Article
VL - 46
SP - 356
EP - 363
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 3
ER -